News
1h
Zacks.com on MSNTempus AI Stock Jumps Post Q2 as EBITDA Breakeven Nears: Buy or Hold?
Tempus AI’s TEM stock has surged nearly 13% since its second-quarter 2025 earnings release. The quarter saw strong top-line ...
Tempus AI achieves strong revenue growth and beats expectations, but ongoing losses and execution risks temper enthusiasm.
4don MSN
Why Tempus AI Stock Jumped Today
The stock of Tempus AI (NASDAQ: TEM) gave back some of its gains after surging early in Friday's trading, but it still ended ...
7don MSN
If You'd Invested $1,000 in Tempus AI Stock (TEM) 1 Year Ago, Here's How Much You'd Have Today
Although shares have retreated from their all-time high, those who bought shares one year ago are still looking at growth in ...
1h
MarketBeat on MSNTempus AI's Strong Q2 Fuels Growth Story-More Upside Ahead?
Over the past two years, one of the most interesting healthcare companies to go public is none other than Tempus AI (NASDAQ: ...
Tempus AI (NASDAQ:TEM) stock sees a 9% pre-market gain as the company raises its 2025 revenue outlook amid strong Q2 ...
12d
Zacks.com on MSNTempus AI Stock Before Q2 Earnings Release: To Buy or Not to Buy?
TEM surged 34.5% in Q2 on AI-driven deals and product momentum, but valuation and profit concerns linger ahead of earnings.
Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting ...
Analysts expect the Chicago, Illinois-based company to report a quarterly loss at 25 cents per share, versus a year-ago loss ...
In trading on the Nasdaq as of 1:17 p.m. Central, Tempus' stock price was $60.65, up 3.2% from the previous day's close.
59m
Investor's Business Daily on MSNDow Jones Futures: Is Stock Market Rotating? Cisco Falls Late; This Cathie Wood, Nancy Pelosi Pick Is A Buy
AI losses and some new leadership hint at a possible stock market rotation. Cisco fell late. Cathie Wood and Nancy pick ...
It marks the second time Tempus AI has received FDA clearance for a cardiovascular product suite.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results